High Throughput Tool Development for Accelerated CAR Engineering

We are using a gene editing and multiparametric single-cell analysis platform to accelerate the discovery of CARs with novel functions

Recent studies have determined that not all CARs are created equal in terms of effector function, persistence, and antigen sensitivity. Our laboratory has developed powerful T cell editing tools which allow for high throughput screening of CAR constructs, as well as discovery of new CAR architectures with augmented effector functions, persistence and sensitivity to antigen density.

Selected Publications

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency.

Nature Medicine 25, 82–88 (2019)

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape.

Nature 568, 112–116 (2019)

Research Team

Alexis Talbot

Postdoctoral Scholar (2020–2023), Current Position: Assistant Professor, Saint-Louis University Hospital, University of Paris

Amrik Kang

MSTP Student

Chang Liu

Research Associate

Charlotte Wang

NSF GRFP Graduate Student

Chris Chang

MSTP Student

News

Media highlights of Eyquem Lab's research.

Peptide-mediated CRISPR engineering of cells

Peptide-RNP delivery paper highlighted by Nature Biomedical Engineering

HIT-T cell paper highlighted in Cancer Cell

Response to Low Antigen Density Is Improved by HLA-Independent T-cell Receptors

AACR 2018: An off-the-shelf, dual-targeted CAR T-cell product showed promising results in preclinical studies

CRISPR gene therapy is enhancing t-cell immnotherapy treatment of cancer and treatments in people could be available within 2 to 3 years

Curing Cancer with CRISPR

Researchers Use CRISPR Gene-Editing Tool to Help Turn Immune Cells against Tumors

Pancreatic cancer cells digest extracellular protein

CRISPR-driven CARs

Using CRISPR to Supercharge Cancer-Killing Immune Cells